An audit of weight and height monitoring in young people on methylphenidate attending a national child and adolescent mental health community clinic (CYPS)

Abstract

BACKGROUND: Attention deficit hyperactivity disorder is one of the neurodevelopmental disorders often seen in young people. The core symptoms include inattention, hyperactivity and impulsivity. .NICE guidelines recommend different treatments for ADHD and the first line pharmacological treatment advised is Methylphenidate. Regular monitoring of weight and height is advised by NICE guidelines for young people on Methylphenidate, as it may cause weight loss and growth retardation. The aim of this audit was to assess compliance with NICE guidelines regarding height and weight monitoring in young individuals attending a National Child and Adolescent Mental Health Community Clinic and receiving methylphenidate treatment.

METHOD: Retrospective case note analysis was carried out on a sample of 287 young people actively attending the National Child and Adolescent Mental Health Community Clinic. Analysis was focused on determining whether weight and height were being monitored according to guidelines. Factors contributing to inadequate monitoring were identified and the presence of comorbid mental disorders were also noted. Additional data, such as demographics and type of methylphenidate treatments, were also recorded.

RESULTS: Results revealed that weight was monitored according to guidelines in 31.36% whilst weight was monitored in 25.09% of cases. Height and weight were both adequately monitored in 25.09% of the sample. Reasons for under reporting of weight and height and the frequency of other comorbid disorders were also identified.

CONCLUSION: This audit highlights the need for improved weight and height monitoring of young people on methylphenidate. Different strategies can be implemented to facilitate adherence to monitoring guidelines and ensure the availability of accurate data for healthcare professionals involved in patient follow-up.